WillScot Announces Investor Conference Schedule for September 2026

SCOTTSDALE, Ariz., Sept. 15, 2026 (GLOBE NEWSWIRE) -- WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary flexible space solutions, today announced that it will participate in the following investor conferences over the upcoming weeks:

• D.A. Davidson Diversified Industrials & Services Conference
  Date: September 24, 2026
  Location: Nashville, Tennessee

• Deutsche Bank Leveraged Finance Conference
  Date: September 29, 2026
  Location: Scottsdale, Arizona

Portfolio managers and analysts who wish to request a meeting should contact their sales representative at the sponsoring firms.

About WillScot

WillScot (Nasdaq: WSC) is a leading provider of innovative turnkey space solutions in North America, helping customers keep projects moving and operations running. The Company partners with critical industries including construction, manufacturing, healthcare, government, energy and education to deliver the right solutions coupled with a high level of customer service. WillScot’s comprehensive portfolio of products – including modular complexes, dry and cold storage containers, blast-resistant buildings, clearspan industrial structures, fencing, and add-on furnishings and equipment – is customizable and flexible to support any project need. Headquartered in Scottsdale, Ariz., WillScot operates from a network of approximately 240 branch locations in the U.S., Canada, and Mexico.

Additional information can be found on the company's website at www.willscot.com.

Contact Information

Investor inquiries:
Charlie Wohlhuter
[email protected]

Media inquiries:
Juliana Welling
[email protected]

You May Also Be Interested In

• AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations
• Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
• Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and